Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Genentech Showcases New Clinical Data across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
November 3, 2016 12:30 PM EDTNew results from the Phase III GALLIUM study which compared Gazyva® (obinutuzumab) plus chemotherapy to Rituxan® (rituximab) plus chemotherapy in previously untreated follicular lymphoma will be presented in the Plenary Scientific Session New results for Venclexta (venetoclax) and investigational medicine emicizumab will also be presented at the meeting FDA has accepted the Biologics License Application for a subcutaneous formulation of Rituxan® (rituximab/hyaluronidase)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:... More
Rogers Corporation Reports Results for the 2016 Third Quarter
November 2, 2016 4:23 PM EDTNet sales of $165.3 million, up 3.1% Gross margin of 37.5%, up 30 basis points Net income of $16.1 million, up 28.1% Adjusted EBITDA of $34.1 million, 20.6% of net sales
ROGERS, Conn.--(BUSINESS WIRE)-- Rogers Corporation (NYSE: ROG) today announced financial results for the 2016 third... More
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
November 2, 2016 1:00 AM EDT15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra data from GiACTA - the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy in more than 50 years New data from two studies investigating cardiovascular outcomes for people with rheumatoid arthritis (RA) treated with Actemra
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),... More
